Amy Jacob

Rosa Michaelis, MD, discusses her goals of cultivating more patient interaction within epilepsy research at the American Epilepsy Society 2014 Annual Meeting.

The US Food and Drug Administration (FDA) approved today Xtoro (finafloxacinotic suspension), a novel drug treatment for acute otitis externa, otherwise known as swimmer's ear, an infection within the outer ear and ear canal, typically caused by bacteria festered in the ear canal.

An international team of researchers recently reported that inhibiting a nuclear receptor in the gut could spur favorable treatment for nonalcoholic fatty liver disease (NAFLD), in which buildup of fat in liver cells disrupts liver function.

Different brands of FITs with the same cutoff hemoglobin concentration have been reported to perform differently in detection of colorectal cancer (CRC).

Franck Kalume, PhD, shared the potential possibility for treatment options for both geriatric and pediatric epilepsy patients at the American Epilepsy Society 2014 Annual Meeting.

Franck Kalume, PhD, discusses his lab's primary research focus at the American Epilepsy Society 2014 Annual Meeting.

Helen Scharfman, PhD, discusses the next steps of her research study at the American Epilepsy Society 2014 Annual Meeting.

Helen Scharfman, PhD, shares her physiological approach to epilepsy management at the American Epilepsy Society 2014 Annual Meeting.

Kimford J. Meador, MD speaks about the neurodevelopment effects of combination drug exposure in women with epilepsy at the American Epilepsy Association 2014 Annual Meeting.

Laura Jansen, MD, PhD, speaks about her experiences with management and treatment of pediatric epilepsy at the American Epilepsy Society 2014 Annual Meeting.

W. Curt LaFrance, Jr., MD, MPH shares his views on combining neurological and psychological approaches to epilepsy management and treatment at the American Epilepsy Society 2014 Annual Meeting.

Kathleen Millen, PhD, one of the presenters at the American Epilepsy Society Annual Meeting provided an overview of the diagnosis and treatment of epilepsy in patients with malformations of cortical development.

Results from a recent study show that weak bile acid absorption leads to chronic diarrhea among cancer patients.

The US Food and Drug Administration (FDA) announced today the approval of a new use for Jakafi (ruxolitinib) to treat patients afflicted with polycythemia vera, a chronic type of bone marrow disease associated with phlebitis, splenomegaly, and other potentially severe symptoms.

According to a recent study published in JAMA Dermatology, a longer wavelength laser is an effective treatment option for keratosis pilaris (KP), a skin condition in which skin proteins form hard plugs within hair follicles, for improving skin roughness and textural irregularities.

Although the introduction of peroral endoscopic myotomy (POEM) for the treatment of achalasia, a condition that affects the ability of the esophagus to move food into the stomach, has caused quite a stir, clinicians are reminded to consider additional factors when discussing therapeutic options.

Amgen and AstraZeneca recently announced AMAGINE-2TM, a pivotal, multi-arm Phase 3 clinical trial, met all primary endpoints for brodalumab, an experimental drug designed for moderate to severe plaque psoriasis treatment.

Study results published in the European Respiratory Journal show that rates of inflammatory bowel disease (IBD) incidence have significantly increased in individuals with asthma or chronic obstructive pulmonary disease (COPD).

Regeneron Pharmaceuticals, Inc. and Sanofi recently announced the US food and Drug Administration (FDA) granted Breakthrough Therapy designation to dupilumab, a fully-human monoclonal antibody, to treat adults suffering from moderate to severe atopic dermatitis (AD)who had an insufficient response to or who were not suitable for topical prescription therapy.

Patients with advanced colorectal cancer previously only had access to limited treatment options; however, new research presented at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, indicated a combination of 3 targeted drugs could potentially serve as a successful treatment.

A presentation at the American Heart Association (AHA) Scientific Sessions 2014 suggested, STEMI victims treated with oxygen endured 25 to 30% more heart damage than patients not given oxygen.

A study presented at the American Heart Association (AHA) Scientific Sessions 2014 reported home exercise could potentially alleviate feelings of hopelessness in people afflicted with coronary heart disease.

Results from the pivotal US trial of an everolimus-eluting bioabsorbable polymer-coated stent, the Boston Scientific SYNERGY coronary stent system, indicate that it performs just as well as existing alternatives.

The study of complex congenital cardiac anatomy has previously been limited to 2-dimensional assessment. Now the potential use of 3-dimensional cardiac models could allow for previously unavailable visualization and analysis of anatomy.

"Is this the end of the road for aspirin in primary prevention?" asked Dorairaj Prabhakaran, MD, DM, MSc, at the 2014 American Heart Association (AHA) Scientific Sessions.

Adults whose mothers were overweight prior to pregnancy have a higher risk of dying from cardiovascular disease, according to new research presented at the American Heart Association (AHA) Scientific Sessions 2014.

High trans fat consumption is linked to poor memory among middle-aged men, according to research presented at the American Heart Association (AHA) Scientific Session 2014.

During a question-and-answer session at the American Heart Association (AHA) Scientific Sessions 2014, Stefania Schüpke, MD discussed the results of her ISAR-SAFE study of the dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation is still unknown.

Heart failure is highly debilitating and life threatening – nearly half the patients who die from cardiovascular causes do so suddenly when their heart simply stops pumping, well before medical intervention is even possible.

Kirk Garratt, MD, presenting at the 2014 American Heart Association Scientific Sessions, said "The TAXUS Liberte Post-approval Study (TL-PAS) was designed to provide long-term safety and efficacy information about the clinical outcomes for the TL stent combined with the use of prasugrel and aspirin."